

PRESS RELEASE

Stockholm, 26 May 2014



Sobi appoints Kirsti Gjellan as Senior Vice President Manufacturing Operations

Swedish Orphan Biovitrum AB (publ) (Sobi) today announced that Kirsti Gjellan has been appointed Senior Vice President Manufacturing Operations. Gjellan joins Sobi from global pharmaceutical company Pfizer where she has been Managing Director and Site Leader at the Strängnäs site for Pfizer Health AB as well as Member of the Pfizer Health AB Board.

A Ph.D. in Pharmaceutical Technology, Kirsti Gjellan brings a strong track record from leading positions within both Pfizer and AstraZeneca. She has experience from working both with quality and manufacturing and her achievements have been both internally and externally awarded. In 2006 Gjellan was honoured with Pfizer's John Mitchell Quality Award and in 2013 she was named Swedish Pharma Profile of the Year.

"We are delighted to welcome Kirsti to Sobi", said Geoffrey McDonough, President and CEO at Sobi. "Kirsti will continue to build on the legacy of our biologics manufacturing organisation, and to prepare us for our future products for patients with rare diseases. Kirsti will also be a great addition to our senior leadership team."

"I'm very much looking forward to my new role and to, together with Sobi's Leadership team and all new colleagues, work to bring new therapies for rare diseases to patients who don't have access to medicines today," said Kirsti Gjellan.

Kirsti Gjellan will join Sobi in September 2014. She takes over after Lena Nyström who will retire later this year.

About Sobi

Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Inflammation and Genetic diseases, with two late stage biological development projects within Haemophilia. We also market a portfolio of specialty and rare disease products for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2013, Sobi had total revenues of SEK 2.2 billion (\$334 M) and about 550 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com.

Swedish Orphan Biovitrum AB

Postal address SE-112 76 Stockholm, Sweden

Phone: +46 697 20 00 Fax +46 697 20 00 www.sobi.com

PRESS RELEASE

Stockholm, 26 May 2014



For more information – not for publication

Media relations

Oskar Bosson, Head of Communications

T: +46 70 410 71 80

oskar.bosson@sobi.com

Investor relations

Jörgen Winroth, Vice President, Head of Investor Relations

T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135

jorgen.winroth@sobi.com

The above information was released for public distribution on 26 May 2014, at 15:30 CET.

Swedish Orphan Biovitrum AB

Postal address SE-112 76 Stockholm, Sweden

Phone: +46 697 20 00 Fax +46 697 20 00 www.sobi.com